Stock Ratings / Health Care / DYAI / earnings

BCDA (49) ATYR (44) PLUR (39) SCLX (52) ⌘ Pro Terminal →

Dyadic International Inc. (DYAI) Next Earnings Date & Expected ±12.5% Move

$0.36 -8.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Dyadic International Inc. (DYAI) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $14.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-11.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DYAI)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.04 Expected Swing

MODEL EARNINGS SETUP GAUGE

DYAI Quantitative Pre-Earnings Setup: 33/100

Trailing EPS: $4.25 • YoY Revenue Growth: -11.6%

Model Bullish Setup (33/100)Model Risk Weight (67/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$3.1M	-$7.4M	-$5.7M	24.9%
FY 2024	2024-12-31	$3.5M	-$5.8M	-$4.0M	65.8%
FY 2023	2023-12-31	$2.9M	-$6.8M	-$6.7M	24.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DYAI)

✓Walkthrough of DYAI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DYAI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.85%⚡ TESTING RESISTANCE

2026-10-30O $0.36H $0.40L $0.36C $0.36VOL 111.5K

RES: $0.38SUP: $0.21SMA50: $0.47SMA200: $0.76

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DYAI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DYAI Butterfly Map → + Track DYAI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -11.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DYAI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DYAI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DYAI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DYAI)

Health Care Rank #879 of 1016 ⚔️ BCDA vs DYAI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DYAI vs. BCDA, ATYR, PLUR, SCLX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Dyadic International Inc. (DYAI) ranks #879 by composite RQD confidence (33/100, grade E) and #860 by equity capitalization ($14.5M). Within this direct 5-issuer industry benchmark cohort, DYAI leads on earnings valuation at N/A trailing P/E, while DYAI leads on capital efficiency and profitability with -35.0% ROIC and 24.9% gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with DYAI at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DYAI ACTIVE Dyadic International Inc.	E	33/100	—	24.9%	-35.0%	-8.40%	$14.5M	Benchmark Subject
BCDA BioCardia Inc.	D	49/100	—	—	-35.0%	-2.26%	$14.0M	/bcda-vs-dyai →
ATYR aTyr Pharma Inc.	D	44/100	—	—	-35.0%	+4.56%	$13.5M	/atyr-vs-dyai →
PLUR Pluri Inc.	D-	39/100	—	49.0%	-35.0%	-2.44%	$16.1M	/plur-vs-dyai →
SCLX Scilex Holding Company	D+	52/100	—	96.0%	-35.0%	-1.43%	$17.5M	/sclx-vs-dyai →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001213809

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dyadic International Inc. (DYAI) reported GAAP revenue of $3.1M (-11.6% vs. FY2024 revenue of $3.5M , and +6.6% cumulative change since FY2023) , GAAP net income of -$7.4M, operating cash flow of -$5.7M, and free cash flow of -$5.7M (-43.5% YoY). On the balance sheet, DYAI closed FY2025 with $9.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.1M	-$7.4M	-$5.7M	-$5.7M	$9.9M	—
FY2024 (FY)	2024-12-31	$3.5M	-$5.8M	-$4.0M	-$4.0M	$9.9M	—
FY2023 (FY)	2023-12-31	$2.9M	-$6.8M	-$6.7M	-$6.7M	—	—

3. DYAI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DYAI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Dyadic International Inc. (NASDAQ: DYAI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.36 (-8.40% 1D, market cap $14.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DYAI ranks #879 in composite RQD confidence.

How does DYAI compare to BCDA and ATYR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DYAI carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 24.9%, and ROIC of -35.0%. By comparison, BCDA (BioCardia Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $14.0M) and ATYR (aTyr Pharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, DYAI leads on earnings multiple (N/A) while DYAI leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DYAI?

Per DYAI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213809), Dyadic International Inc. generated $3.1M in revenue (-11.6% YoY), -$7.4M in net income, and -$5.7M in free cash flow against $9.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DYAI trading relative to its 50-day, 200-day, and 52-week technical levels?

DYAI last traded at $0.36 (-8.40% on volume of 79,378 shares), positioning the stock -23.40% below its 50-day simple moving average ($0.47) and -52.63% below its 200-day simple moving average ($0.76). Across its 52-week range of $0.34 to $1.60, DYAI sits at the 1.6% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.40).